Literature DB >> 27324777

Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.

Victoria J Savage1, Cédric Charrier1, Anne-Marie Salisbury1, Helen Box1, Nathan Chaffer-Malam1, Anthony Huxley1, Ralph Kirk1, Gary M Noonan1, Sarfraz Mohmed1, Mark W Craighead1, Andrew J Ratcliffe1, Stuart A Best1, Neil R Stokes2.   

Abstract

There is an urgent need for new antibiotics to treat multidrug-resistant Neisseria gonorrhoeae In this report, the microbiology, in vivo pharmacokinetics, and efficacy of REDX05931, a representative novel tricyclic topoisomerase inhibitor, were evaluated. REDX05931 demonstrated high oral bioavailability in mice and reduced N. gonorrhoeae infection after a single dose in a mouse model of gonorrhea. These data support the potential of this series of small molecules as a new treatment for drug-resistant gonorrheal infections.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27324777      PMCID： PMC4997832          DOI： 10.1128/AAC.00913-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 2.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice.

Authors:  A E Jerse
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Authors:  D J Biedenbach; S K Bouchillon; M Hackel; L A Miller; N E Scangarella-Oman; C Jakielaszek; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

6.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

7.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

8.  Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae.

Authors:  Tomoko Morita-Ishihara; Magnus Unemo; Kei-Ichi Furubayashi; Takuya Kawahata; Ken Shimuta; Shu-Ichi Nakayama; Makoto Ohnishi
Journal:  J Antimicrob Chemother       Date:  2014-04-28       Impact factor: 5.790

9.  Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV.

Authors:  Victoria J Savage; Cédric Charrier; Anne-Marie Salisbury; Emmanuel Moyo; Henry Forward; Nathan Chaffer-Malam; Richard Metzger; Anthony Huxley; Ralph Kirk; Mario Uosis-Martin; Gary Noonan; Sarfraz Mohmed; Stuart A Best; Andrew J Ratcliffe; Neil R Stokes
Journal:  J Antimicrob Chemother       Date:  2016-03-30       Impact factor: 5.790

Review 10.  Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.

Authors:  Magnus Unemo
Journal:  BMC Infect Dis       Date:  2015-08-21       Impact factor: 3.090
View more
  3 in total

1.  Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.

Authors:  R Kirk; A Ratcliffe; G Noonan; M Uosis-Martin; D Lyth; O Bardell-Cox; J Massam; P Schofield; S Hindley; D R Jones; J Maclean; A Smith; V Savage; S Mohmed; C Charrier; A-M Salisbury; E Moyo; R Metzger; N Chalam-Judge; J Cheung; N R Stokes; S Best; M Craighead; R Armer; A Huxley
Journal:  RSC Med Chem       Date:  2020-09-18

2.  In Vitro and In Vivo Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae.

Authors:  Aiko Masuko; Iichiro Takata; Kiyoko Fujita; Hirotoshi Okumura; Fumihito Ushiyama; Hideaki Amada; Hiroyuki Sugiyama
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection.

Authors:  Kristie L Connolly; Michelle Pilligua-Lucas; Carolina Gomez; Allison C Costenoble-Caherty; Anthony Soc; Knashka Underwood; Andrew N Macintyre; Gregory D Sempowski; Ann E Jerse
Journal:  J Infect Dis       Date:  2021-08-16       Impact factor: 7.759
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.